- Bloomberg
Alnylam Soars After Drug Meets Goal in Heart Disease Trial
(Bloomberg) -- Alnylam Pharmaceuticals Inc. shares soared after its drug succeeded in treating a progressive and deadly form of heart disease, potentially opening up a new avenue for the company’s top-selling product. Most Read from BloombergJain Global Raises $5.3 Billion, Secures Cash From Abu DhabiHow Long Can High Rates Last? Bond Markets Say Maybe ForeverBuzzFeed Struggles to Sell Owner of Hit YouTube Show ‘Hot Ones’Tech Hits Stocks as Nvidia Extends Selloff to 13%: Markets WrapNvidia Sales
- Insider Monkey
Did Seagen Acquisition Help Pfizer Inc. (PFE) Increase Revenue in Q1?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other healthcare stocks. You can also check out the 20 Most Valuable Healthcare Companies in the World here. Healthcare stocks are […]
- Motley Fool
2 Beaten-Down Growth Stocks to Buy Without Hesitation in the 2024 Bull Market
Price only tells you part of the story.
